Quoin Pharmaceuticals, Ltd.
QNRX
$7.20
-$0.0796-1.09%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.02M | 5.83M | 5.82M | 5.87M | 5.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.68M | 11.03M | 9.53M | 9.34M | 8.94M |
| Operating Income | -12.68M | -11.03M | -9.53M | -9.34M | -8.94M |
| Income Before Tax | -12.17M | -10.45M | -8.96M | -8.70M | -8.28M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.17 | -10.45 | -8.96 | -8.70 | -8.28 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.17M | -10.45M | -8.96M | -8.70M | -8.28M |
| EBIT | -12.68M | -11.03M | -9.53M | -9.34M | -8.94M |
| EBITDA | -12.58M | -10.93M | -9.43M | -9.24M | -8.84M |
| EPS Basic | -1.45K | -1.71K | -2.84K | -4.95K | -6.77K |
| Normalized Basic EPS | -25.90 | -30.52 | -50.66 | -88.35 | -120.86 |
| EPS Diluted | -1.46K | -1.72K | -2.84K | -4.95K | -6.77K |
| Normalized Diluted EPS | -25.90 | -30.52 | -50.66 | -88.35 | -120.86 |
| Average Basic Shares Outstanding | 1.51M | 1.06M | 535.60K | 376.90K | 260.80K |
| Average Diluted Shares Outstanding | 42.90K | 30.20K | 15.20K | 10.70K | 7.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |